Institution Directory

Clinical trials at Penn Medicine (University of Pennsylvania)

Sites in Philadelphia, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 7:36 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1357

Shown on this page

Current sort

Live official records

Conditions: Giant Cell Arteritis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 50 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 5
States / cities: Rochester, Minnesota • New York, New York • Cleveland, Ohio + 2 more

Conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm
Interventions: Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide, Vorinostat; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2027
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 14 more

Conditions: Fibromyalgia
Interventions: Focused Ultrasound; Device
Lead sponsor: SPIRE Therapeutics Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 8
States / cities: Ann Arbor, Michigan • Minneapolis, Minnesota • St Louis, Missouri + 5 more

Conditions: Primary Cutaneous Vasculitis, Cutaneous Polyarteritis Nodosa, IgA Vasculitis, Henoch-Schönlein Purpura
Interventions: Colchicine, Dapsone, Azathioprine; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 12
States / cities: Kansas City, Kansas • Boston, Massachusetts • Rochester, Minnesota + 9 more

Conditions: Aneurysm, Dissection, Aortic Root Aneurysm, Aortic Root Dissection, Carotid Artery Injuries, Aortic Arch, Bypass Extremity Graft, Occlusive Vascular Disease, Aortic Diseases
Interventions: Gelsoft Plus Vascular Graft, Vascular Bypass Graft, Cardiovascular Patch, Gelweave Vascular Graft, Gelweave Valsalva Vascular Graft; Device
Lead sponsor: Vascutek Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2037
U.S. locations: 10
States / cities: Aurora, Colorado • Tampa, Florida • Indianapolis, Indiana + 7 more

Conditions: Stroke, Stroke, Acute, Stroke, Ischemic
Interventions: Transcranial Magnetic Stimulation (TMS); Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 45
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 37 more

Conditions: Castleman Disease, Castleman's Disease, Multicentric
Interventions: Sirolimus; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 2 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: Little Rock, Arkansas • Philadelphia, Pennsylvania

Conditions: Hypothyroidism Primary
Interventions: Liothyronine (L-T3), Levothyroxine Sodium (LT4) Tablets, Liothyronine (LT3) placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chin Regression, Chin Asymmetry, Jawline Contour Deficit
Interventions: HA Filler; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 22 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
Interventions: Vepugratinib, Pembrolizumab, enfortumab vedotin, Trastuzumab Deruxtecan, Midazolam, Digoxin, Rosuvastatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 677 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 41
States / cities: Tucson, Arizona • Duarte, California • Los Angeles, California + 29 more

Conditions: Myotonic Dystrophy Type 1 (DM1)
Interventions: VX-670, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: San Carlos, California • Gainesville, Florida • Fairway, Kansas + 5 more

Conditions: Myocarditis Acute, Cancer
Interventions: Abatacept plus, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 29
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 21 more

About this Penn Medicine (University of Pennsylvania) institution page

What this page lists: ClinicalTrials.gov records that list Penn Medicine (University of Pennsylvania) in Philadelphia, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Penn Medicine (University of Pennsylvania)

Filter and sort this campus

Live official records

Abatacept for the Treatment of Giant Cell Arteritis

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

Ultrasonic Neuromodulation of Cingulate Cortex for Fibromyalgia

A Randomized Multicenter Study for Isolated Skin Vasculitis

PANTHER Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches

Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials

Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease

T4/T3 Therapy in Hypothyroidism

Evaluation of Filler Injection for Chin Profile Enhancement

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

Abatacept in Immune Checkpoint Inhibitor Myocarditis

About this Penn Medicine (University of Pennsylvania) institution page